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A B S T R A C T
Purpose: In this prospective study, we compared the long-term cognitive and behavioral effects of
lamotrigine (LTG) and carbamazepine (CBZ) in patients with newly diagnosed or untreated partial
epilepsy.
Methods: This was a multicenter, open-label, randomized study that compared monotherapy with LTG
and CBZ in newly diagnosed or untreated patients with partial epilepsy. We employed an 8-week
titration period and a 40-week maintenance period. Neuropsychological tests, Symptom Check List-90,
and QOLIE-31 were assessed at baseline, 16 weeks, and 48 weeks after drug treatment. A group-by-time
interaction was the primary outcome measure and was analyzed by use of the linear mixed model.
Results: A total of 110 patients were eligible and 73 completed the 48-week study (LTG, n = 39; CBZ,
n = 34). Among the cognitive tests, signiﬁcant group-by-time interactionwas identiﬁed only in phonemic
ﬂuency of Controlled Oral Word Association Task (p = 0.0032) and Stroop Color–Word Interference
(p = 0.0283), with a signiﬁcant better performance for LTG group. All other neuropsychological tests
included did not show signiﬁcant group-by-time interactions. Among the subscales of Symptom Check
List-90, signiﬁcant group-by-time interactions were identiﬁed in Obsessive-Compulsive (p = 0.0005),
Paranoid Ideation (p = 0.0454), Global Severity Index (p = 0.0194), and Positive Symptom Total
(p = 0.0197), with a signiﬁcant improvement for CBZ group. QOLIE-31 did not show signiﬁcant group-
by-time interactions.
Conclusion: Our data suggest that epilepsy patients on LTG have better performance on phonemic ﬂuency
and the task of Stroop Color–Word Interference than do patients on CBZ, whereas patients on CBZ had
more favorable behavioral effects on two subscales and two global scores of Symptom Check List-90 than
did patients on LTG.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Patients with epilepsy are more likely to have cognitive
impairment than healthy individuals. The duration of epilepsy,
underlying pathology, seizure frequency, and use of an antiepilep-
tic drug (AED) inﬂuence the cognitive function of patients with
epilepsy. AED-induced cognitive impairment appears to be less
common in patients taking newer AEDs than in those taking older
AEDs.1,2* Corresponding author. Tel.: +82 2 3010 3445; fax: +82 2 474 4691.
E-mail address: salee@amc.seoul.kr (S.-A. Lee).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.10.006Lamotrigine (LTG) is an AED that appears to be associated with
fewer cognitive and behavioral changes than are many other
AEDs.3,4 Existing data suggest that the cognitive deﬁcits commonly
associated with AED therapy are rarely observed in patients
receiving LTG monotherapy.5,6 When LTG is used as an add-on
therapy, existing cognitive problems are not exacerbated, and, in
some cases, become less severe.5–7
A randomized, monotherapy clinical trial of newly diagnosed
epilepsypatients is the bestmethod toassess the cognitive impact of
AEDs. Such a study is not confounded by the effect of concurrent or
previous AED use, and allows accurate collection of baseline data,
which are required to determine whether a drug affects cognitive
processing.8 A large number of cognitive studies have investigatedvier Ltd. All rights reserved.
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carbamazepine (CBZ) monotherapy in patients with newly diag-
nosed epilepsy. Brodie et al.9 investigated the long-term effects of
LTG and CBZ on the cognitive function of patients with newly
diagnosed epilepsy, and concluded that LTG may have a more
favorable effect on cognitive function. However, the cited studywas
not published in full, and only the abstract is available.
The current randomized prospective investigation was
designed to compare the long-term cognitive and behavioral
effects of LTG and CBZ in adult patients with newly diagnosed or
untreated partial epilepsy. CBZ was chosen as the active
comparator because this is often the treatment-of-choice for
monotherapy of patients with partial epilepsy. With the exception
of slowing the speed of information processing, CBZ does not




In this study, we analyzed the cognitive data of newly
diagnosed or untreated patients with partial epilepsy by use of
a multicenter, open-label, randomized, parallel-group comparison
of LTG and CBZ, given as monotherapy. This study consisted of an
8-week titration period and a 40-week maintenance period.
Cognitive data frompatientswho completed the entire 48weeks of
the trial were evaluated.
2.2. Patients
Patients, aged 16–60 years, with newly diagnosed partial
epilepsywere eligible for inclusion.We also included patients with
partial epilepsy who were recently untreated for at least one year.
All enrolled patients had at least one partial seizure, with or
without secondary generalization, in the 12 months before
commencement of the study. We excluded patients who used
any AED treatment within the past one year (except as an
emergency treatment for 2 weeks); those with full-scale
intelligence quotient (FSIQ) less than 70; and those with idiopathic
generalized epilepsy, an active CNS infection, any progressive CNS
disease, or any medical or neurological disorder that required
frequent changes inmedication or dosage. The studywas approved
by local ethics committees and was conducted in accordance with
Good Clinical Practice and the Declaration of Helsinki. Each
participant gave written informed consent.
2.3. Dosing
Patients were randomized tomonotherapy with LTG or CBZ in a
1:1 ratio, in blocks of four. During the 8-week titration period,
patients received LTG as follows: 25 mg/day for weeks 1–2, 50 mg/
day for weeks 3–4, 100 mg/day for weeks 5–6, and 200 mg/day for
weeks 7–8. During the maintenance period, the LTG dose was
increased to a maximum of 500 mg/day if the patient continued to
experience seizures. Patients receiving CBZ were dosed as follows:
100 mg/day for weeks 1–2, 200 mg/day for weeks 3–4, 400 mg/day
for weeks 5–6, and 600 mg/day for weeks 7–8. During the
maintenance period, the CBZ dose was increased to a maximum
of 1200 mg/day if the patient continued to experience seizures.
Controlled-release preparations of CBZ were used. Exit criteria
based on insufﬁcient efﬁcacy were: (i) occurrence of a seizure
during the maintenance period despite administration of the drug
at themaximum allowed dose or themaximum tolerated dose and
(ii) a maximum tolerated dose less than 100 mg/day of LTG or
400 mg/day of CBZ. Both drugs were administered as two divideddoses per day. The doses of drugs were determined by seizure
recurrence and drug tolerance.
2.4. Neuropsychological tests
Cognitive function was evaluated at baseline, at week 16, and at
week 48 using a range of neuropsychological tests that measure
general intellectual ability, learning and memory, attention, and
executive function.General intellectual abilitywasassessedemploy-
ing the short form of the Korean Wechsler Adult Intelligence Scale-
Revised using four subtests of the scale: Vocabulary, Arithmetic,
PictureCompletion,andBlockDesign.12Verbal learningandmemory
wereassessedwith theKoreanCaliforniaVerbal LearningTest13: List
A acquisition, immediate and delayed free recall, recognition hits,
and discriminability. Visuospatial constructional ability and visuo-
spatial memory were assessed with the Rey Complex Figure Tests:
copy, immediate recall, delayed recall, and recognition.
Complex attention and executive function were assessed with
the Digit Span (forward and backward), Trail Making Test Parts A
and B, and Stroop Color–Word Interference Test. Stroop Color–
Word Interference14 was measured with the difference in time
taken by subjects to perform the interference subtask compared
with the subtasks of color naming or reading. Verbal ﬂuency was
assessed by the Controlled OralWord Association Task15 (COWAT),
in which participants had to say as many words as possible from a
category in 60 s. The semantic categories were words related to
animals and supermarkets, and the phonemic categories were
words that began with the Korean letters q (g or k),* (o), and f (s).
Subjective psychological symptoms and health-related quality-
of-life were assessed with the Symptom Check List-9016 (SCL-90)
and the QOLIE-31.17 The SCL-90 is a 90-item multidimensional
questionnaire designed to screen for a broad range of psychological
problems. The subscales included are nine primary symptom
dimensions: Somatization, Obsessive-Compulsive, Interpersonal
Sensitivity, Depression, Anxiety, Anger-Hostility, Phobic Anxiety,
Paranoid Ideation, and Psychoticism. Three ‘‘global’’ scores are also
obtained: the Global Severity Index, The Positive Symptom
Distress Index, and the Positive Symptom Total. The subscales of
QOLIE-31 include evaluation of seizure worry, overall quality-of-
life, emotional well-being, energy/fatigue, cognitive functioning,
medication effects, and social functioning.
2.5. Statistical analyses
All patients whowere given neuropsychological tests at baseline
and at 16- and 48-week follow-ups were included in this analysis.
The primary outcome measure was a group-by-time interaction,
which was analyzed using a linear mixed model. Analyses of group
effects and time effects were performed only when there was a
signiﬁcant group-by-time interaction. The model included treat-
ment group, time, and group–time effects as ﬁxed, and hospital
effects as random. A covariance pattern was constructed for
repeated observations by the same patients. Stroop Color–Word
Interferencewas analyzed after log-transformation, because it has a
right-skeweddistribution. Themodel included adjustedvariables as
ﬁxed effects. The adjusted variables were age, gender, years of
education, FSIQ, and presence of seizure recurrence during the
maintenance period. Signiﬁcance level was set at p 0.05. Data
were analyzed using SAS version 9.1 (SAS Institute, Cary, NC).
3. Results
3.1. Demographics and clinical data
We enrolled 116 patients, with 57 randomized to receive LTG
and 53 to receive CBZ (Fig. 1). Six patients dropped out before
[(Fig._1)TD$FIG]
Fig. 1. Patient disposition by treatment arm.
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low FSIQ scores (2 patients). Seventy-three patients successfully
continued treatment until the week-48 follow-up (LTG, n = 39,
68.4%; CBZ, n = 34, 64.2%). In the LTG group, the reasons for
discontinuation were withdrawal of consent (n = 7), adverse
events (n = 4), lack of efﬁcacy (n = 4), loss to follow-up (n = 2),
and protocol violation (FSIQ less than 70) (n = 1). All adverse events
were developing skin rashes. In the CBZ group, the reasons for
discontinuation were loss to follow-up (n = 7), adverse events
(n = 7), lack of efﬁcacy (n = 2), withdrawal of consent (n = 2),
protocol violation (more than 2 weeks of emergency treatment)
(n = 1). Among adverse events in CBZ group, skin rashes were in 5
patients, car accident (not directly related to CBZ) was in one
patient, andmitral stenosis (not directly related to CBZ) was in one
patient. Patientswho completed the studywerewellmatchedwith
respect to demographic and clinical characteristics (Table 1). The
percentage of patients with no seizures was not signiﬁcantly
different between the groups during the maintenance period
(71.8% LTG, 64.7% CBZ; p > 0.05). At the 16-week and 48-week
follow-ups, the average daily dose of medication was 217 mgTable 1
Demographic and clinical characteristics of subjects at baseline.
Male/female, no
Age, mean (SD) (years)
Age at seizure onset, mean (SD) (years)
Duration of epilepsy, mean (SD) (years)





History of previous antiepileptic treatments
History of febrile convulsion
History of head trauma prior to seizure onset
Family history of epilepsy
Full-scale intelligence quotient, mean (SD)
Education, mean (SD) (years)
Dosage at week-16, mean (SD) (mg/day)
Dosage at week-48, mean (SD) (mg/day)
Seizure freedom during the maintenance period(SD = 45 mg) and 236 mg (SD = 81 mg) in the LTG group, and
605 mg (SD = 104 mg) and 647 mg (SD = 164 mg) in the CBZ group.
3.2. Cognitive data
Signiﬁcant group-by-time interaction was identiﬁed only in
the phonemic ﬂuency of COWAT (p = 0.0032) and Stroop Color–
Word Interference (p = 0.0283), with the LTG group performing
signiﬁcantly better (Table 2). The CBZ and LTG groups did not
differ signiﬁcantly at baseline. However, the LTG group was
signiﬁcantly better than the CBZ group in phonemic ﬂuency at
both 16 (p = 0.0062) and 48 (p = 0.0032) weeks and in Stroop
Color–Word Interference (p = 0.0229) at 48 weeks (Table 2). Time
effects were signiﬁcant only in the LTG, not in the CBZ, group. In
the LTG group, phonemic ﬂuencywas signiﬁcantly better, relative
to baseline, at 16 (p = 0.0003) and 48 (p < 0.0001) weeks, and
Stroop Color–Word Interference was signiﬁcantly better at 48-
weeks (p = 0.0002). All other cognitive tests, including those of
language and memory, did not show signiﬁcant group-by-time
interactions (Tables e-1 and e-2).Lamotrigine (n=39) Carbamazepine (n=34)
19/20 23/11
34.8 (13.6) 36.8 (10.4)
29.3 (14.2) 29.7 (12.7)
5.5 (7.9) 7.2 (10.4)
3.6 (6.4) 3.6 (5.6)
25 (64.1%) 21 (61.8%)
9 (23.1%) 8 (23.5%)
5 (12.8%) 5 (14.7%)
10 (25.6%) 6 (17.6%)
4 (10.3%) 5 (15.2%)
7 (17.9%) 9 (27.3%)
4 (10.3%) 4 (12.9%)
105.0 (12.0) 103.0 (15.3)
12.6 (2.7) 12.8 (2.9)
217 (45) 605 (104)
236 (81) 647 (164)
28 (71.8%) 22 (64.7%)
Table 2
Signiﬁcant group-by-time interaction using linear mixed model for Controlled Oral Word Association Task.
Group-by-time
p-Value
Time Group effect Estimate Standard error p-Value Group Time effect Estimate Standard error p-Value
Phonemic ﬂuency 0.0032 LTG V3–V0b 4.5570 1.2276 0.0003
V0 LTG–CBZa 1.2166 2.1872 0.5792 V7–V0 6.4872 1.2164 <0.0001
V3 LTG–CBZ 6.1579 2.2040 0.0062 CBZ V3–V0 0.3843 1.3167 0.7708
V7 LTG–CBZ 6.9097 2.1872 0.0021 V7–V0 0.7941 1.3028 0.5432
Stroop Word/Color Interference 0.0283 LTG V3–V0 0.1744 0.0896 0.0536
V0 LTG–CBZa 0.0466 0.1238 0.7071 V7–V0 0.3343 0.0888 0.0002
V3 LTG–CBZ 0.2223 0.1245 0.0764 CBZ V3–V0 0.0945 0.0952 0.3221
V7 LTG–CBZ 0.2849 0.1238 0.0229 V7–V0 0.0028 0.0952 0.9765
LTG, lamotrigine; CBZ, carbamazepine; V0, a baseline visit; V3, a visit at 16-week; V7, a ﬁnal visit at 48-week.
a Difference in test score in the lamotrigine group minus those in the carbamazepine group.
b Difference in test score at 16-week (V3) or 48-week (V7) minus score of a baseline test (V0).
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Signiﬁcant group-by-time interactions were identiﬁed in Obses-
sive-Compulsive (p = 0.0005), Paranoid Ideation (p = 0.0454), Global
Severity Index (p = 0.0194), andPositive SymptomTotal (p = 0.0197)
scores of the SCL-90 (Table 3), with signiﬁcant improvements in the
CBZ group. Obsessive-Compulsive subscale did not differ between
the CBZ and LTG groups at baseline, but was signiﬁcantly better in
the CBZ than in the LTG group at 48 weeks (p = 0.0427). In addition,
the Obsessive-Compulsive subscale was signiﬁcantly improved at
48-weeks, compared with baseline, in the CBZ (p = 0.0012), but not
in the LTG, group. Paranoid Ideation, Global Severity Index, and
Positive Symptom Total showed signiﬁcant time effects but not
groupeffects. Allwere signiﬁcantly improved, relative tobaseline, at
48-weeks (p < 0.05) in the CBZ group but not in the LTG group. In
contrast, the LTG group showed a signiﬁcant improvement, relative
to baseline, on Positive Symptom Total at 16 (p = 0.0129) but not at
48 weeks. The other dimensions of the SCL-90 (Table e-3) and the
total and subscale scores of the QOLIE-31 (Table e-4) did not show
any signiﬁcant group-by-time interactions.
4. Discussion
We compared the cognitive and behavioral long-term effects of
LTG and controlled-release CBZ in adult patients with newly
diagnosed or untreated partial epilepsy. LTG-treated patients
performed better than CBZ-treated patients on phonemic verbal
ﬂuency of COWAT and selective attention measured by Stroop
Color–Word Interference, but the two groups did not differ inTable 3
Signiﬁcant group-by-time interaction using linear mixed model for Symptom Checklis
Group-by-time
p-Value
Time Group effect Estimate Standa
Obsessive-Compulsive 0.0005
V0 LTG–CBZa 0.9342 2.5512
V3 LTG–CBZ 0.3852 2.5518
V7 LTG–CBZ 5.2237 2.5389
Paranoid Ideation 0.0454
V0 LTG–CBZ 0.3406 1.8500
V3 LTG–CBZ 0.4884 1.8509
V7 LTG–CBZ 3.2536 1.8374
Global Severity Index 0.0194
V0 LTG–CBZ 0.8908 2.2102
V3 LTG–CBZ 0.02144 2.2110
V7 LTG–CBZ 3.1593 2.1994
Positive Symptom Total 0.0197
V0 LTG–CBZ 1.3231 2.6488
V3 LTG–CBZ 2.0728 2.6500
V7 LTG–CBZ 3.0084 2.6340
LTG, lamotrigine; CBZ, carbamazepine; V0, a baseline visit; V3, a visit at 16-week; V7,
a Difference in test score in the lamotrigine group minus those in the carbamazepin
b Difference in test score at 16-week (V3) or 48-week (V7) minus score of a baselinlanguage, memory function, and other executive functions. In
contrast, the CBZ group showed more positive behavioral effects
than did the LTG group.
LTG has not been associated with impaired cognitive function-
ing, and use of LTG may lead to improvements in cognition and
associated measures of health-related quality of life.4–6 However,
few randomizedmonotherapy studies have assessed the long-term
cognitive impact of LTG, especially in patients with newly
diagnosed epilepsy. The short-term cognitive effects of LTG have
been evaluated in healthy volunteers,5,18 as add-on therapy,6,7 and
in comparison with active comparators other than CBZ.5,6 Long
term treatment with LTG may result in types of cognitive
impairments that cannot be observed during short-term treat-
ment.4 Except for an abstract,9 this is the ﬁrst study to compare the
long-term effects of LTG and CBZ on the cognitive function of
patients newly diagnosed with epilepsy. That study9 evaluated the
long-term cognitive effects of LTG and CBZ, over 48 weeks, in
patients newly diagnosed with epilepsy. Among the neuropsycho-
logical tests performed in that study were verbal learning and
memory tests (e.g. Verbal Learning I and II, Delayed Recall, and
Recognition) and attention and mental ﬂexibility (e.g. Semantic
Processing I and II, Trail Making test, Logical Reasoning and Stroop
Test). Signiﬁcant differences favoring LTG over CBZ were observed
in Semantic Processing, Verbal Learning, and the Stroop Test. These
results, except for those on the Stroop Test, differed somewhat
from our ﬁndings. Overall, the cognitive proﬁles of our LTG and CBZ
groups did not differ, with no between-group differences in
language, memory function, and semantic ﬂuency. However, we
found that phonemic verbal ﬂuency and Stroop Color–Wordt List-90.
rd error p-Value Group Time effect Estimate Standard error p-Value
LTG V3–V0b 0.4510 1.1972 0.7070
0.7151 V7–V0 2.0696 1.1743 0.0802
0.8804 CBZ V3–V0 1.0000 1.2338 0.4190
0.0427 V7–V0 4.0882 1.2338 0.0012
LTG V3–V0 0.5533 1.0539 0.6004
0.8543 V7–V0 0.9765 1.0342 0.3467
0.7924 CBZ V3–V0 1.3824 1.0870 0.2056
0.0797 V7–V0 2.6176 1.0870 0.0174
LTG V3–V0 1.6895 1.0547 0.1115
0.6879 V7–V0 0.2146 1.0345 0.8360
0.9923 CBZ V3–V0 2.5588 1.0870 0.0200
0.1545 V7–V0 4.2647 1.0870 0.0001
LTG V3–V0 3.4262 1.3602 0.0129
0.6186 V7–V0 0.9626 1.3344 0.4719
0.4361 CBZ V3–V0 2.6765 1.4023 0.0584
0.2564 V7–V0 5.2941 1.4023 0.0002
a ﬁnal visit at 48-week.
e group.
e test (V0).
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patients. Our ﬁndings, along with those reported previously,9
suggest that LTG may have a favorable long-term effect on
cognitive function when compared with CBZ.
Short-term volunteer studies using a double-blind, randomized
crossover design with two 10- or 12-week treatment periods were
performed to evaluate the relative cognitive and behavioral effects
of LTG compared with CBZ18 or topiramate,5 respectively. In both
studies, the LTG group showed signiﬁcantly better performance on
a wide variety of objective and subjective neuropsychological
measures when compared with CBZ and topiramate, respectively.
A double-blind, randomized, prospective comparison of the
cognitive effects of LTG and topiramate, which was used as
adjunctive therapy in adults with epilepsy, with an 8-week
titration period followed by an 8-week maintenance period,
showed that LTG resulted in better performance than topiramate
on the COWAT, Stroop Color–Word Interference, and Symbol–Digit
Modalities tests.6
Although our study did not include a no-drug group, the
signiﬁcant difference between the LTG and CBZ groups was likely
caused by decreased performance on the phonemic verbal ﬂuency
and Stroop Color–Word Interference tasks in the CBZ group, which
manifested as negation of the practice effect. The practice effect is
one of the most signiﬁcant confounding inﬂuences encountered in
studies that employ follow-up testing performance. Practice effects
canoccurevenaftera time intervalofnearly1year.19Previousshort-
term studies on healthy volunteers also indicated adverse cognitive
effects of CBZ compared with LTG or gabapentin.18,20
Our CBZ group showed more positive behavioral effects than
did the LTGgroup. Among the subscales and global indexes of SCL-
90, Obsessive-Compulsive, Paranoid Ideation, Global Severity
Index, and Positive Symptom Total found that only CBZ patients
showed signiﬁcant improvements at 48 weeks. In contrast, the
LTG group showed signiﬁcant improvements on the Positive
Symptom Total only at 16 weeks, but not at 48 weeks, compared
with baseline. CBZ was initially developed to treat individuals
with epilepsy but was subsequently found to have diverse
psychotropic effects, most notably in mood-stabilization.21–23
In addition, CBZ has been reported to effectively reduce
Obsessive-Compulsive symptoms in patients with epilepsy24,25
and may have antidepressant effects.26,27 Thus, CBZ appears to
elicit diverse neurochemical effects, but which of these effects is
most closely related to its antidepressant effects, compared with
its antimanic and anticonvulsant effects, remains to be deter-
mined.28
Previous studies of LTG in patients with epilepsy showed an
apparently independent improvement in depression apart from
reductions in seizure frequency.29–32 Most of the cited studies
assessed only short-term drug effects (less than 7 months). In this
study, the LTG group also showed signiﬁcant improvements on the
Positive Symptom Total of SCL-90. But these favorable behavioral
effects were observed only at 16 weeks, but not at 48 weeks, when
compared with baseline. We need further long-term studies to
clarify the long-term effects of LTG on mood in patients with
epilepsy.
LTG has been also shown to be effective for treatment of bipolar
disorder based on long-term trials.33,34 However, this study did not
demonstrate long-term effects of LTG on mood and behavior. The
reason for this discrepancywas unclear. A nonrandomized study in
35 adults with partial epilepsy found no appreciable effects on
mood changes, when measured with various established depres-
sion and anxiety scales, with LTG of mean 150 mg/day for
approximately 3.5 months.35 This may have been a result of the
low LTG dosages used in these patients. In our study, LTG dosages
were not low. The mean dosage of the study was 236 mg/day at
week-48. An 18-month trial of LTG maintenance treatment inrecently depressed patients with bipolar I disorder showed that
LTG 200 mg/day group had signiﬁcant efﬁcacy including time to
intervention for a mood episode and one-year intervention-free
rate for depression.34 Another possible explanation is that LTG
could have different effects on mood in different disease entities.
Several previous studies using validated scales showed that LTG
treatment was associated with improved quality-of-life.4,5,18,36
However, very few randomized controlled studies have examined
the long-term effects of AEDs on quality-of-life. Marson et al.37
reported 2-year follow-up results on quality-of-life in adult patients
taking CBZ or other new AEDs as part of a large, unblinded,
randomized controlled trial. The cited authors found no signiﬁcant
differences in quality-of-life among those taking different drugs.
Their resultswere consistentwith those in this study. Another study
involved a double-blind comparison of LTG andCBZ in patientswith
newly diagnosed epilepsy, in which 260 patients were randomized
to 48weeks of LTG or CBZ.38 Quality-of-life wasmeasured using the
modiﬁed SEALS Inventory. When changes in quality-of-life were
evaluated within groups for patients who completed this 48-week
study, theSEALS scores in theLTGgroup improvedsigniﬁcantly from
baseline on all subscales after 48 weeks, but CBZ patients
experienced no signiﬁcant change in subsequent SEALS assess-
ments. These ﬁndings are somewhat inconsistent with our results.
We found no signiﬁcant differences in quality-of-life among those
taking CBZ or LTG.
The results of this study must be interpreted with some
caution. First, the sensitivity of detecting putative changes after
AED treatment may differ by type of cognitive tests.39 Therefore,
the lack of differential effects could be caused by non-sensitive
cognitive tasks. In contrast, mood and subjective symptoms may
be more sensitive than objective cognitive tests to the effects of
AED. Second, the effects on the 34% of randomized subjects who
did not complete the study were not considered. Some of these
non-completers could dropped out, withdraw their consent, or be
lost follow-up due to cognitive ormood adverse events. Third, our
data were pooled frommultiple hospitals to increase the number
of patients. We believe, however, that confounding factors were
minimized because neuropsychologists from each hospital met
three times before the start of the study to minimize methodo-
logical differences and inter-hospital effects. Fourth, this was a
randomized but unblinded study.
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